IMPORTANT PROGRAM UPDATE AS OF MARCH 2025
The U.S. Food and Drug Administration (FDA) has determined the approved Risk Evaluation and Mitigation Strategies (REMS) for TRYVIO ™ are no longer necessary to ensure the benefits of the drug outweigh the risk of embryo-fetal toxicity. Prescribers and pharmacies are no longer required to interact with the REMS.